Citations

Clear

1526 citation(s) found for "Sun, Yu".

Monoclonal Antibody Specific to Acid Phosphatase Isoenzyme 4
Dang, H, Lam, Kwok‐Wai , Li, C.-Y., Wold, Lester E., Yam, L T, Li, C.-Y., Sun, Tsieh

Mayo Clinic

Journal of Urology | June 29, 2017 | Volume: 138 | Issue: 2 | Pages: 458-459

10.1016/s0022-5347(17)43201-0 Get It

EFFECT OF COLLAGEN CONCENTRATIONS ON THE CONTRACTION AND MATERIAL PROPERTIES OF BONE MARROW STROMAL CELL-SEEDED GEL(3A2 Cellular & Tissue Engineering & Biomaterials II)
Chieh, Hsiao-Feng, Omae, Hiromichi, Liao, Jiunn‐Der , An, Kai‐Nan, Sun, YuLong, Su, Fong‐Chin

Mayo Clinic

The Proceedings of the Asian Pacific Conference on Biomechanics : emerging science and technology in biomechanics | June 19, 2017 | Volume: 2007.3 | Pages: S173

10.1299/jsmeapbio.2007.3.s173 Get It

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons
Donohue, Michael , Petersen, Ronald C. , Sun, Chung‐Kai , Weiner, Michael W. , Aisen, Paul , Initiative, for the Alzheimer’s Disease Neuroimaging, Sperling, Reisa Anne , Initiative, for the Alzheimer’s Disease Neuroimaging, Donohue, Michael C

Mayo Clinic

JAMA | June 13, 2017 | Volume: 317 | Issue: 22 | Pages: 2305

10.1001/jama.2017.6669 | PMID 28609533 Get It

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kondrashova, Olga , Nguyen, Minh , Shield‐Artin, Kristy , Tinker, Anna V. , Teng, Nelson N.H., Harrell, Maria I., Barker, Holly E. , Prakash, Rohit , Kass, Elizabeth M. , Sullivan, Meghan R. , Brunette, Gregory J. , Bernstein, Kara A. , Floquet, Anne , Friedländer, Michael , O’Malley, David M. , Oza, Amit M. , Robillard, Liliane, Maloney, Lara , Bowtell, David D.L. , Giordano, Heidi, Wakefield, Matthew J. , Simmons, Andrew D. , Harding, Thomas C., Raponi, Mitch , McNeish, Iain A. , Swisher, Elizabeth M. , Scott, Clare L. , Lin, Kevin K. , Kaufmann, Scott H. , Kuiper, Michael J. , Ho, Gwo‐Yaw , Jasin, Maria , Sullivan, Meghan R. , Coleman, Robert L. , Kichenadasse, Ganessan , Sun, James X. , Lin, Kevin , McNeish, Iain A , Swisher, Elizabeth M , Friedlander, Michael , Wakefield, Matthew J , Scott, Clare L , Bernstein, Kara A , Kondrashova, Olga , Bowtell, David D , Barker, Holly E , O'Malley, David M

Mayo Clinic

Cancer Discovery | June 6, 2017 | Volume: 7 | Issue: 9 | Pages: 984-998

10.1158/2159-8290.cd-17-0419 | PMID 28588062 Get It

Abstract High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism. We sequenced core HR pathway genes in 12 pairs of pretreatment and postprogression tumor biopsy samples collected from patients in ARIEL2 Part 1, a phase II study of the PARPi rucaparib as treatment for platinum-sensitive, relapsed ovarian carcinoma. In 6 of 12 pretreatment biopsies, a truncation mutation in BRCA1, RAD51C, or RAD51D was identified. In five of six paired postprogression biopsies, one or more secondary mutations restored the open reading frame. Four distinct secondary mutations and spatial heterogeneity were observed for RAD51C. In vitro complementation assays and a patient-derived xenograft, as well as predictive molecular modeling, confirmed that resistance to rucaparib was associated with secondary mutations. Significance: Analyses of primary and secondary mutations in RAD51C and RAD51D provide evidence for these primary mutations in conferring PARPi sensitivity and secondary mutations as a mechanism of acquired PARPi resistance. PARPi resistance due to secondary mutations underpins the need for early delivery of PARPi therapy and for combination strategies. Cancer Discov; 7(9); 984–98. ©2017 AACR. See related commentary by Domchek, p. 937. See related article by Quigley et al., p. 999. See related article by Goodall et al., p. 1006. This article is highlighted in the In This Issue feature, p. 920
Development and validation of a nomogram to estimate the pretest probability of cancer in Chinese patients with solid solitary pulmonary nodules: A multi‐institutional study
She, Yunlang , Zhao, Lilan , Dai, Chenyang , Ren, Yijiu , Jiang, Gening , Xie, Huikang , Zhu, Huiyuan , Sun, Xiwen , Shi, Shunbin, Shi, Weirong, Xie, Dong , Chen, Chang , Yang, Ping , Chen, Yongbing , Yu, Bing

Mayo Clinic

Journal of Surgical Oncology | June 1, 2017 | Volume: 116 | Issue: 6 | Pages: 756-762

10.1002/jso.24704 | PMID 28570780 Get It

ObjectivesTo develop and validate a nomogram to estimate the pretest probability of malignancy in Chinese patients with solid solitary pulmonary nodule (SPN).Materials and MethodsA primary cohort of 1798 patients with pathologically confirmed solid SPNs after surgery was retrospectively studied at five institutions from January 2014 to December 2015. A nomogram based on independent prediction factors of malignant solid SPN was developed. Predictive performance also was evaluated using the calibration curve and the area under the receiver operating characteristic curve (AUC).ResultsThe mean age of the cohort was 58.9 ± 10.7 years. In univariate and multivariate analysis, age; history of cancer; the log base 10 transformations of serum carcinoembryonic antigen value; nodule diameter; the presence of spiculation, pleural indentation, and calcification remained the predictive factors of malignancy. A nomogram was developed, and the AUC value (0.85; 95%CI, 0.83‐0.88) was significantly higher than other three models. The calibration cure showed optimal agreement between the malignant probability as predicted by nomogram and the actual probability.ConclusionsWe developed and validated a nomogram that can estimate the pretest probability of malignant solid SPNs, which can assist clinical physicians to select and interpret the results of subsequent diagnostic tests.
BCL6 represses antiviral resistance in follicular T helper cells
Amet, Tohti, Son, Young Min , Jiang, Li , Cheon, In Su , Huang, Su, Gupta, Samir K. , Montaner, Luis J. , Yu, Qigui , Dent, Alexander L. , Sun, Jie

Mayo Clinic

Journal of Leukocyte Biology | May 27, 2017 | Volume: 102 | Issue: 2 | Pages: 527-536

10.1189/jlb.4a1216-513rr | PMID 28550121 Get It

Abstract Follicular Th (Tfh) cells are a distinct subset of Th cells that help B cells produce class-switched antibodies. Studies have demonstrated that Tfh cells are highly prone to HIV infection and replication. However, the molecular mechanisms underlying this phenomenon are largely unclear. Here, we show that murine and human Tfh cells have diminished constitutive expression of IFN-stimulated genes (ISGs) inclusive of antiviral resistance factor MX dynamin-like GTPase 2 (MX2) and IFN-induced transmembrane 3 (IFITM3) compared with non-Tfh cells. A lower antiviral resistance in Tfh was consistent with a higher susceptibility to retroviral infections. Mechanistically, we found that BCL6, a master regulator of Tfh cell development, binds to ISG loci and inhibits the expression of MX2 and IFITM3 in Tfh cells. We demonstrate further that inhibition of the BCL6 BR-C, ttk, and bab (BTB) domain function increases the expression of ISGs and suppresses HIV infection and replication in Tfh cells. Our data reveal a regulatory role of BCL6 in inhibiting antiviral resistance factors in Tfh cells, thereby promoting the susceptibility Tfh cells to viral infections. Our results indicate that the modulation of BCL6 function in Tfh cells could be a potential strategy to enhance Tfh cell resistance to retroviral infections and potentially decrease cellular reservoirs of HIV infection.
Disrupted functional connectivity between perirhinal and parahippocampal cortices with hippocampal subfields in patients with mild cognitive impairment and Alzheimer's disease
Lu, Jiaming , Liu, Rengyuan, Zhao, Hui , Xu, Lingyi, Zhu, Bin , Liu, Bing , Wan, Suiren , Xu, Yun , Sun, Yu , Wang, Yafei , Schwarz, Christopher G. , Zhang, Yue , Zhang, Bing

Mayo Clinic

Oncotarget | May 17, 2017 | Volume: 8 | Issue: 58 | Pages: 99112-99124

10.18632/oncotarget.17944 | PMID 29228757 Get It

Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
Jones, Jeremy , Renfro, Lindsay A. , Al‐Shamsi, Humaid O. , Schrock, Alexa B. , Rankin, Andrew, Zhang, Ben Y., Kasi, Pashtoon Murtaza , Voss, Jesse S. , Leal, Alexis D. , Ali, Siraj M. , Kipp, Benjamin R. , Kopetz, Scott , Wolff, Robert A. , Jones, Jeremy C., Kasi, Pashtoon M, Sun, James, Ross, Jeffrey , Hubbard, Joleen M. , McWilliams, Robert R. , Jones, Jeremy C , Kasi, Pashtoon Murtaza , Sun, James X. , Ross, Jeffrey S , Grothey, Axel , Kopetz, Scott , Al-Shamsi, Humaid O

Mayo Clinic

Journal of Clinical Oncology | May 9, 2017 | Volume: 35 | Issue: 23 | Pages: 2624-2630

10.1200/jco.2016.71.4394 | PMID 28486044 Get It

Purpose Molecular diagnostic testing has become an integral part of the evaluation of patients with metastatic colorectal cancer (CRC). Expanded mutational testing, such as next-generation sequencing (NGS), often identifies mutations with unclear clinical or prognostic implications. One such example is BRAF mutations that occur outside of codon 600 (non-V600 BRAF mutations). Methods We conducted this multicenter, retrospective cohort study to characterize the clinical, pathologic, and survival implications of non-V600 BRAF mutations in metastatic CRC. We pooled patients in whom non-V600 BRAF mutations were identified from NGS databases at three large molecular genetics reference laboratories. Results A total of 9,643 patients with metastatic CRC underwent NGS testing. We identified 208 patients with non-V600 BRAF mutations, which occurred in 2.2% of all patients tested and accounted for 22% of all BRAF mutations identified. Cancers with non-V600 BRAF mutations, compared with cancers with V600E BRAF (V600E BRAF) mutations, were found in patients who were significantly younger (58 v 68 years, respectively), fewer female patients (46% v 65%, respectively), and patients who had fewer high-grade tumors (13% v 64%, respectively) or right-sided primary tumors (36% v 81%, respectively). Median overall survival was significantly longer in patients with non-V600 BRAF-mutant metastatic CRC compared with those with both V600E BRAF-mutant and wild-type BRAF metastatic CRC (60.7 v 11.4 v 43.0 months, respectively; P < .001). In multivariable analysis, non-V600 BRAF mutation was independently associated with improved overall survival (hazard ratio, 0.18; P < .001). Conclusion Non-V600 BRAF mutations occur in approximately 2.2% of patients with metastatic CRC and define a clinically distinct subtype of CRC with an excellent prognosis.
Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report
Schriber, Jeffrey, Ahn, Kwang Woo , Fei, Mingwei , Costa, Luciano J. , Kharfan-Dabaja, M A, Angel-Diaz, Miguel, Ganguly, Siddharatha, Girnius, Saulius, Hashmi, Shahrukh K. , Pawarode, Attaphol , Vesole, David H. , Wiernik, Peter H. , Wirk, Baldeep , Marks, David I. , Olsson, Richard F. , Usmani, Saad Z. , D’Souza, Anita , Hashmi, Shahrukh, D'Souza, Anita , Hari, Parameswaran , Gale, Robert Peter , Nishihori, Taiga , Mark, Tomer M , Nieto, Yago , Olsson, Richard F , Costa, Luciano J , Usmani, Saad

Mayo Clinic

Cancer | May 4, 2017 | Volume: 123 | Issue: 16 | Pages: 3141-3149

10.1002/cncr.30747 | PMID 28472539 Get It

BACKGROUNDRace/ethnicity remains an important barrier in clinical care. The authors investigated differences in the receipt of autologous hematopoietic cell transplantation (AHCT) among patients with multiple myeloma (MM) and outcomes based on race/ethnicity in the United States.METHODSThe Center for International Blood and Marrow Transplant Research database was used to identify 28,450 patients who underwent AHCT for MM from 2008 through 2014. By using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 registries, the incidence of MM was calculated, and a stem cell transplantation utilization rate (STUR) was derived. Post‐AHCT outcomes were analyzed among patients ages 18 to 75 years who underwent melphalan‐conditioned peripheral cell grafts (N = 24,102).RESULTSThe STUR increased across all groups from 2008 to 2014. The increase was substantially lower among Hispanics (range, 8.6%‐16.9%) and non‐Hispanic blacks (range, 12.2%‐20.5%) compared with non‐Hispanic whites (range, 22.6%‐37.8%). There were 18,046 non‐Hispanic whites, 4123 non‐Hispanic blacks, and 1933 Hispanic patients. The Hispanic group was younger (P < .001). Fewer patients older than 60 years underwent transplantation among Hispanics (39%) and non‐Hispanic blacks (42%) compared with non‐Hispanic whites (56%). A Karnofsky score <90% and a hematopoietic cell transplantation comorbidity index score >3 were more common in non‐Hispanic blacks compared with Hispanic and non‐Hispanic whites (P < .001). More Hispanics (57%) versus non‐Hispanic blacks (54%) and non‐Hispanic whites (52%; P < .001) had stage III disease. More Hispanics (48%) versus non‐Hispanic blacks (45%) and non‐Hispanic whites (44%) had a very good partial response or better before transplantation (P = .005). Race/ethnicity did not impact post‐AHCT outcomes.CONCLUSIONSAlthough the STUR increased, it remained low and was significantly lower among Hispanics followed by non‐Hispanic blacks compared with non‐Hispanic whites. Race/ethnicity did not impact transplantation outcomes. Efforts to increase the rates of transplantation for eligible patients who have MM, with an emphasis on groups that underuse transplantation, are warranted. Cancer 2017;123:3141–9. © 2017 American Cancer Society.